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ABSTRACT
Sema4D (CD100), a member of the neuro-semaphorin family of proteins, has recently been shown to play a
role in modulating certain immune responses. We tested the requirement of Sema4D expression on T cells in
the induction of T cell allo-immune responses. Sema4D/ T cells showed reduced expansion in vitro upon
stimulation with allo-geneic antigen presenting cells (APCs) when compared to wild-type (wt) T cells. Similar
in vitro results were observed using anti-Sema4D mAbs. Further studies demonstrated that the reduced
proliferation was not due to intrinsic T cell defects, and that the cytotoxic functions were preserved. After
allo-geneic bone marrow transplant (BMT), recipients of Sema4D/ T cells showed reduced mortality and
graft-versus-host disease (GVHD) target organ damage. Allo-geneic dendritic cells (DCs) cocultured with
Sema4D/ responder T cells secreted less TNF- and IL-12p70 compared to wt T cells. Similar reduction
of DC function was observed with anti-Sema4D mAbs. Given the preservation of CTL function we evaluated
graft-versus-leukemia (GVL) responses. When BALB/c recipient mice were challenged with the P815 murine
mastocytoma cell line (H2d) the recipients of allo-geneic Sema4D/ B6 T cells showed a significant
improvement in tumor free survival when compared to syngeneic recipients, thus demonstrating preservation
of GVL, albeit of a lesser magnitude than allo-geneic wt T cells. In summary, Sema4D plays a significant role
in mediating in vitro and in vivo allo-geneic responses by modulating T cell-APC interactions.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Sema4D (CD100), a 150-kDa transmembrane
rotein, belongs to the family of semaphorins [1-4],
hich are chemorepulsive factors needed for the guid-
nce of axons to target cells to establish neuronal
ynapses. Sema4D is highly expressed in secondary
ymphoid organs such as the lymph nodes and spleen,
nd is constitutively expressed on naïve T cells.
ema4D has recently been shown to have immuno-
odulatory functions in autoimmune diseases [5-11].
D72, a C type lectin, is the ligand for Sema4D in the
mmune system [5,12]. It is expressed on the surface of
ntigen presenting cells (APCs) such as B cells and
Cs, suggesting that Sema4D-CD72 interaction l
294odulates immune responses. Absence of Sema4D
oes not cause differences in the surface phenotype,
umbers, and ratios of T and B cells between
ema4D/ and wild-type (wt) mice [11]. However,
ema4D deﬁciency has been shown to cause dysregu-
ated B cell responses, whereas Sema4D transgenic
nimals show enhanced B cell activation and antibody
roduction [13]. Kumanogoh and colleagues [10] also
howed impaired priming of Sema4D/ T cells in
he context of experimental autoimmune encephalo-
yelitis (EAE). In these studies, Sema4D-deﬁcient
nimals were resistant to EAE, wheras wt mice suc-
umbed to the disease. These observations suggested
hat Sema4D might have an important role in regu-
ating T cell function. However, the role of Sema4D
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CD100 and Allo-responses 1295n regulating T cell allo-responses is not known. We
herefore utilized a well-characterized murine model
f graft-versus-host (GVHD) and graft-versus-leuke-
ia (GVL) to evaluate the role of Sema4D in modu-
ating allo-responses.
Acute GVHD (aGVHD) is a major complication
n allo-geneic bone marrow transplantation (BMT)
hat is caused by donor T cells [14-16]. Donor T cells
ncounter with allo-antigen on APCs [16] is critical
or the induction of GVHD. The secretion of pro-
nﬂammatory mediators such as TNF- and IL-12 by
he APCs further enhances the allo-responses of do-
or T cells [17] and aggravates GVHD. We evaluated
he role of Sema4D expression by donor T cells on the
everity of GVHD in a [B6¡BALB/c] MHC mis-
atched model of allo-geneic BMT. Because GVHD
s tightly linked to the beneﬁcial GVL effects after
llo-BMT, we also analyzed the impact of Sema4D
xpression on donor T cells in the antitumor re-
ponses after allo-BMT. We demonstrate that the
bsence or blockade of Sema4D (1) regulated allo-
roliferative responses in vitro, (2) reduced GVHD in
ivo, (3) did not impair the cytolytic T cell responses,
nd (4) preserved GVL effects to a lesser magnitude.
TUDY DESIGN
ice
BALB/c (H-2d), C57BL/6 (H-2b), were purchased
rom Jackson Laboratories (Bar Harbor, ME).
ema4D/ B6 (H-2b) [10] (courtesy of Dr. Kumano-
oh) homozygous animals were bred and maintained
n a speciﬁc free environment in compliance with the
niversity of Michigan Animal Use and Care protocols.
ecipients used for BMT were between the ages of 12
nd 20 weeks, and weighed at least 18 g. All experiments
ere approved by the University of Michigan Commit-
ee on the Use and Care of Animals.
MT
Bone marrow (BM) was harvested from the femurs
nd tibias of donor mice. Cell mixtures of 5 106 BM
ells supplemented with 0.50  106 isolated splenic T
ells from either wt B6 or Sema4D/ with CD90
agnetic beads (Miltenyi-Biotec automated cell
orter) were resuspended in Leibovitz’s L-15 medium
Life Technologies, Grand Island, NY) and trans-
lanted into B6 or BALB/c recipients via tail vein
nfusion (0.25 mL total volume). Before transplant,
ost mice received 8 Gy of total body irradiation
137Cs source) delivered in 2 fractions separated by 3
ours to reduce gastrointestinal toxicity. Mice were
ubsequently housed in sterilized microisolator cages
nd received normal chow and autoclaved hyperchlo-
inated water for the ﬁrst 3 weeks after BMT and
ltered water thereafter. cystemic and Histopathologic Assessment
f GVHD
The degree of systemic GVHD was assessed by a
tandard scoring system as described previously [18-20].
ransplanted mice were ear punched, and individual
eights were obtained and recorded on day 0 and
eekly thereafter. A clinical index was generated
eekly by summation of 5 criteria scores: percentage
f weight change, posture (hunching), activity, fur
exture, and skin integrity (maximum index  10).
nimals that received a score of 6.5 or higher were
umanely euthanized.
aGVHD was also assessed by detailed histopatho-
ogic analysis of the small (ileum) and large (ascend-
ng) intestine. Specimens were harvested from animals
n days 14 and 60, placed in 10% buffered for-
alin, embedded in parafﬁn, cut into 5-m-thick sec-
ions, and stained with hematoxylin and eosin for
istologic examination. Slides were coded without ref-
rence to mouse type or prior treatment status and
xamined systematically by a single pathologist (C. Liu)
sing a semiquantitative scoring system. Speciﬁc param-
ters scored included villous blunting, crypt regenera-
ion, crypt epithelial cell apoptosis, crypt loss, luminal
loughing of cellular debris, lamina propria inﬂamma-
ory cell inﬁltrate, and mucosal ulceration in the small
owel, crypt regeneration, crypt epithelial cell apoptosis,
rypt loss, surface colonocyte vacuolization, surface
olonocyte attenuation, lamina propria inﬂammatory
ell inﬁltrate, and mucosal ulceration in the large bowel
nd portal tract expansion by an inﬂammatory cell inﬁl-
rate, lymphocytic inﬁltrate of bile ducts, bile duct epi-
helial cell apoptosis, bile duct epithelial cell sloughing,
ascular endotheliitis, parenchymal apoptosis, parenchy-
al microabscesses, parenchymal mitotic ﬁgures, hepa-
ocellular cholestasis, and hepatocellular steatosis in the
iver. The scoring system for each parameter that eval-
ated both the extent and severity of tissue damage
enoted 0 as normal, 0.5 as focal and rare, 1 as focal and
ild, 2 as diffuse and mild, 3 as diffuse and moderate,
nd 4 as diffuse and severe.
ixed Leukocyte Reactions and DC Cultures
All culture media reagents were purchased from
ibco BRL (Gaithersburg, MD). For analysis of prolif-
rative response and IFN- production, splenocytes
ere harvested from naïve BALB/c, B6, or Sema4D/
ice. Anti-Sema4D mAbs (courtesy of Dr. Kumanogoh)
ere utilized in the cultures at 1 g/mL [21]. Cells were
uspended in 5% FCS/RPMI supplemented with 50
/mL penicillin, 50 g/mL streptomycin, 2 mM l-
lutamine, 1 mM sodium pyruvate, 0.1 mM nones-
ential amino acid, 0.02 mM -mercaptoethanol, and
0 mM HEPES (pH 7.75). These cells (0.5  105 to
 105) were cultured in ﬂat-bottomed 96-well Fal-on plates (Lincoln Park, NJ) in the presence of irra-
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R. Duran-Struuck et al.1296iated (2000 Rad) splenocytes from naïve BALB/c
nimals at 37°C in a humidiﬁed incubator supple-
ented with 5% CO2. Supernatants were collected at
8 h for IL-2, and IFN- analysis by ELISA, and
roliferative response to host antigen was measured by
1205 Betaplate reader (Wallac, Turku, Finland) after
2-96 hours by incorporation of [3H]thymidine (1 Ci)
or the last 18-24 hours of incubation.
For the DC cultures BM was isolated from BALB/c
emurs and tibias (as described previously) and cultured
or 7 days with GMCSF and 10% DMEM. CD11c
Cs were puriﬁed using CD11c magnetic beads (Milte-
yi-Biotec automated cell sorter) and cocultured for
0-72 hours with CD3 T cells from BALB/c, wt B6	
nti-CD100mAbs or CD100/ animals. TNF- and
L-12p70 supernatants were harvested and measured
ith sandwich ELISA (below).
ytokine ELISA
Concentrations of TNF- IL-12p70, IL-2, and
FN- were measured from serum and cell culture
upernatants in triplicate by sandwich ELISA by using
peciﬁc antimurine MoAbs for capture and detection
nd the appropriate standards: IFN-, IL-2, and IL-
2p70 (BD Pharmingen, San Diego, CA) and TNF-
R&D Systems, Minneapolis, MN). All of the in vitro
ssays were performed more than twice, and the in
ivo analyses were from 7 different mice/group and
un according to the manufacturer’s protocol. Sam-
les were diluted 1:2 to 1:5. ELISA plates were read at
50 nm by using a microplate reader (Bio-Rad Labs,
ercules, CA).
low Cytometric Analysis
A ﬂow cytometric analysis was performed using
ITC, PE, or allyphycocyanin-conjugated monoclo-
al antibodies (mAbs) to mouse CD3, CD8, CD4,
2b (Pharmigen) [22]. To analyze cell surface phe-
otype, splenocytes from naïve or transplanted mice
ere resuspended in PBS and stained as described in
anufacturer’s protocol. In brief, cells (0.5  106)
ere incubated for 20 minutes at 4°C with mAb 2.4G2
o block nonspeciﬁc staining by Fc receptors and then
ith the appropriate conjugated mAbs for 30 minutes
t 4°C. They were subsequently washed twice with
BS/0.2% BSA and ﬁxed in 1% paraformaldehyde.
wo- or 3-color ﬂow cytometric analysis was per-
ormed by using FACS Vantage or FACS Diva SE cell
orter (Becton Dickinson, San Jose, CA).
uciferase P815 Cell Line
P815 leukemia cells were purchased from ATCC
Rockville, MD) and were transduced with a third-
eneration lentivirus coexpressing GFP and ﬁreﬂy lu-
iferase (Luc) [23,24]. Brieﬂy, 0.5  106 fresh P815
ells were suspended in 1 mL of 10% DMEM and 8 (g/mL of polybrene in a 6-well plate. Cells were
entrifuged at 2000 rpm at 32°C for 30 minutes. Cells
ere then cultured for 7 hours at 37°C. One millilter
f fresh media (total 2 mL) was added for overnight
ncubation. On day 2, P815 cells were washed with
resh 10% DMEM and allowed to expand for 24
ours. Stably transduced cells were sorted (FACS
iva) for high expression of GFP and recultured in
itro for 2-4 days with 10% DMEM.
ioluminescence Imaging
Bioluminescence imaging [25] was performed with
cryogenically cooled CCD camera (IVIS, Xenogen,
opkinton, MA). Acquisition and analysis of images
ere performed as previously described [26,27]. All
nimals were imaged 10 minutes after being injected
P with 100 L (40 mg/mL) of ﬁreﬂy D-luciferin
Biosyth, Switzerland). Animals were imaged 5 min-
tes to 30 seconds, depending on the signal strength.
ll animals were maintained under isoﬂurane anesthe-
ia and in a 37°C heated environment.
nduction of Leukemia
The P815 leukemia model was used for the graft-
ersus-leukemia (GVL) experiments [28]. P815 is a
astocytoma (H2d) cell line derived from DBA/2
ouse. On day 0, 400 P815 cells were injected to each
ecipient along with syngeneic (BALB/c) or allo-
eneic (B6) BM and either BALB/c, CD100/ or
6 (wt) CD90 splenic T cells. As few as 100 P815
ells can cause fatal leukemia in syngeneic hosts. P815
ells invade particularly the liver, the lymph nodes,
M, and spleen. Animals were monitored twice daily
or survival and the cause of death determined by
ostmortem gross pathology examination. Tumor
urden was indirectly assessed via in vivo biolumines-
ence to document disease progression over time.
hromium Release Assays
Tumor targets, 2 106 P815 (H2d) or EL4 (H2b),
ere labeled with 100 Ci of 51Cr sodium salt (NEN
ife Sciences Products, Wilmington, DE) for 2 hours.
fter washing, labeled targets were resuspended and
he 51Cr-release assays was performed as described
reviously [28]. Allo-geneic splenocytes were har-
ested and normalized for donor CD8 (CD45.1,
D8) cells on day 14. These preparations were
dded to quadruplicate wells at varying effector-to-
arget ratios and incubated for 4 hours. Maximal and
ackground release was determined by the addition of
riton-X (Sigma, St. Louis, MO) or media alone to
argets, respectively. 51Cr activity in supernatants taken
hours later was determined in an autogamma counterPackard, Downers Grove, IL) as described [28].
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CD100 and Allo-responses 1297tatistical Analysis
Satistical analysis was performed as described ear-
ier [22].The Mann-Whitney U-test was used for the
tatistical analysis of clinical scores, histopathology
cores, and cytometric analysis. The Wilcoxon rank
est was used to analyze survival data. P 
 .05 was
onsidered statistically signiﬁcant.
ESULTS
eficiency of Sema4D Causes Less T Cell
llo-reactivity
We ﬁrst tested the role of Sema4D expression on
cells in modulating in vitro allo-responses. We used
genetic approach by utilizing Sema4D-deﬁcient T
ells as allo-responders in a mixed lymphocyte reac-
ion (MLR) using allo-geneic BALB/c stimulators.
ema4D/ T cells expanded 2-fold less compared
o the wt T cells (P 
 .01) (Figure 1A). Consistent
ith the decreased proliferation, T cell cytokines
FN- (Figure 1B) and IL-2 (Figure 1C) production
as also signiﬁcantly decreased. We next cultured B6
t T cells with anti-Sema4D monoclonal antibodies
mAbs) and irradiated BALB/c splenocytes. Allo-ge-
eic T cells expanded 32% less in the presence of
nti-Sema4D mAbs when compared to controlled
ells (P 
 .01; Table 1). Taken in the context of
igure 1. Deﬁciency of Sema4D decreases cytokine production of
cells and DCs and lowers T cell expansion in an allogeneic in
itro setting. BALB/c stimulators and T cells from either B6 wt
black bars, allogeneic), Sema4D/ (gray bars, allogeneic), or
ALB/c Tc (white bars, syngeneic) were used. A-C, BALB/c
plenocytes irradiated and cocultured with either BALB/c, B6 wt, or
ema4D/ T cells at a 2/1 stimulator/responder ratio. A, Prolif-
ration (72 hours), B, IL-2 production (48 hours), C, IFN- (48
ours). D-E, TNF- and IL12p70 levels measured from superna-
ants in 18-24 hour cocultures with nonirradiated CD11c BALB/c
Cs and BALB/c T cells (white bar), B6 wt T cells (black bars),Aema4D/ T cells (gray bar) at a 2:1 ratio. *P 
 .01, **P 
 .02.revious observations that Sema4D/ T cells pro-
iferated normally to anti-CD3 and concanavilin A
timulation [10], these results demonstrate diminished
esponses by T cells to allo-stimulation but not to
ominal antigens in the presence of monoclonal anti-
ody or with lack of Sema4D expression on T cells.
ema4D Expression on T Cells Modulates
llo-geneic Dendritic Cell Function
Next, we investigated the mechanism of decreased
llo-proliferative responses by the Sema4D/ T
ells. APC function is critical for modulating adaptive
cell responses [29]. Because Sema4D/T cells do
ot have any cell intrinsic defect upon TCR stimula-
ion we hypothesized that Sema4D expression on T
ells modulates T cell responses indirectly. To test our
ypothesis we performed coculture experiments of
Cs, the most potent APCs [30,31], either with wt or
ema4D/T cells. The DC function was determined
y secretion of pro-inﬂammatory cytokines [32] as de-
cribed in Study Design. BALB/c DCs that were cul-
ured with B6 Sema4D/ T cells showed a signiﬁcant
eduction in the secretion of TNF- and IL12p70 (Fig-
re 1D and E) when compared to DCs cultured with wt
cells. To rule out nonspeciﬁc and/or compensatory
ffects of Sema4D/ T cells we performed similar
xperiments in the presence of anti-Sema4D mAbs.
imilar reduction in DC cytokine secretion was ob-
erved in the presence of anti-Sema4D mAbs (Table
). We also assessed for the expression of costimula-
ory molecules (CD80, CD86, and CD40) on the
urface of the DCs [30,33] in these cultures and ob-
erved no statistically signiﬁcant differences between
he groups (data not shown). Collectively, these data
how that expression of Sema4D on allo-T cells en-
ances APC function as determined by cytokine se-
retion without signiﬁcantly altering the phenotype of
able 1. Anti-Sema4D Monoclonal Antibody Effects in Allogeneic
esponses
SYN
wt
(Allo-Control)
wt
(Anti-Sema4DmAbs)
pm 824  445 10,614  900 7229  808*
L-12p70 275  60 377  54 233  39
NF- 50  40 654  57 326  29*
NF- indicates tumor necrosis factor-alpha; SYN, syngeneic; wt,
wild type.
ALB/c stimulators and either BALB/c or wtB6 T cells 	 anti-
Sema4D monoclonal antibody (1 g/mL). BALB/c splenocytes
irradiated and cocultured with T cells at a 2/1 stimulator/
responder ratio. Nonirradiated CD11c BALB/c DCs and
either BALB/c T cells or B6 wt T cells 	 anti-Sema4D mAbs at
a 2:1 ratio where cocultured for the analysis of TNF and
IL-12p70. Cytokine levels measured from supernatants 18-24
hours later.
P 
 .03.PCs.
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R. Duran-Struuck et al.1298ffect of Sema4D on T Cell Cytotoxicity
We next assessed the effects of Sema4D deﬁciency
n T cell-mediated cytotoxic responses. We examined
he allo-speciﬁc cytolytic functions of Sema4D/
nd wt T cells after in vitro priming. wt and
ema4D/ T cells were stimulated with irradiated
ALB/c splenocytes for 5 days. The cells were then
arvested and evaluated for their cytotoxic T lympho-
yte (CTL) function in a chromium release assay
gainst allo-geneic (H2d) P815 target cells. As shown
n Figure 2A, Sema4D/ cytolytic effects were pre-
erved and were comparable to B6 wt T cells. Lack of
igniﬁcant lysis of syngeneic targets demonstrated that
here was no indiscriminate killing of target cells.
ema4D/ Donor T Cells Induce Less Severe
VHD Morbidity and Mortality
We determined the in vivo relevance of Sema4D
n modulating allo-responses. To that end, we used
VHD as a read-out for T cell allo-reactivity in
HC mismatched model of allo-geneic BMT. Based
igure 2. Maintenance of CTL by Sema4D/T cells B6 wt (allog
n vitro for 5 days with irradiated BALB/c (H2d) splenocytes (A) or t
plenocytes were harvested from the cultures on day 5-6 in the i
14 after BMT. CTL assays, normalized for total donor (H2b) CD
gainst allo targets (P815) in wt allo-control (□) versus Sema4D
igniﬁcant lysis of syngeneic targets (EL-4) observed in either of wt
hown.n the in vitro observations and the reductions in T
ell expansion, we hypothesized that Sema4D deﬁ-
iency would reduce GVHD. BALB/c animals were
ransplanted with B6 wt BM along with puriﬁed
plenic T cells from wt or Sema4D/ B6 donors
ollowing lethal irradiation with 800 cGy. Consistent
ith the in vitro data, Sema4D/ donor T cells
howed a signiﬁcant reduction in expansion on day
14 after BMT (Figure 3A). Serum IFN- was sig-
iﬁcantly reduced in recipients of Sema4D/ T
ells compared to animals injected with allo-geneic wt
cells (Figure 3B). Allo-geneic animals that received
6 Sema4D/ T cells exhibited signiﬁcantly less
eight loss (Figure 3E), less severe GVHD (Figure 3F),
nd mortality (P 
 .02) (Figure 3D) when compared
o the recipients of wt T cells. As expected, all synge-
eic recipients of wt T cells were alive by day 60.
urthermore, syngeneic control animals that received
ema4D/T cells also demonstrated 100% survival
howing that homeostatic expansion of Sema4D/
cells did not affect overall survival.
2b) or Sema4D/ (allogeneic H2b) CD90T cells were cultured
nted into irradiated BALB/c mice (B) as described in Study Design.
priming experiments (A) or from recipients (n  5/group) on day
, and used in a 51Cr-release assay. Cytotoxic T lymphocyte activity
(‘) groups. Lysis in allo-geneic groups was similar, whereas no
Sema4D/ ()groups. Data from 1 of 2 similar experiments areeneic H
ranspla
n vitro
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CD100 and Allo-responses 1299ema4D/ T Cells Reduce Target Organ
amage and Improve Immune Reconstitution
fter Allo-geneic BMT
Next, we conﬁrmed the reduction of GVHD by
istopathologic analysis of the GVHD target organs,
iver, skin, and intestines, on day 60 post-BMT. As
hown in Figure 4A-C, allo-geneic recipients of
ema4D/ T cells showed reduced GVHD target
rgan damage when compared to recipients of wt T
ells. Similar reductions were also observed on day 14
data not shown). On day 14, wt and Sema4D/
llo-T cell recipients demonstrated comparable donor T
ell chimerism thus indicating that alterations in the
egree of mixed chimerism was not a cause for the
eduction in GVHD (Figure 3C).
We next assessed the degree of immune reconsti-
ution after allo-BMT. We analyzed T cell and other
onor cell lineages in the spleen of recipient mice at
he end of the observation period as a marker for
mmune reconstitution. Consistent with reduced
VHD results, the overall splenic cellularity (Figure
D), the numbers of donor CD3 T cells and CD4,
nd CD8 T cell subsets (Figure 4E) were signiﬁcantly
etter in the allo-recipients of Sema4D/ T cells.
hese data demonstrate that allo-recipients of
ema4D/ T cells show an improvement in im-
une reconstitution when compared to recipients of
igure 3. Sema4D/ T cell recipients have improved survival
ecipients were lethally irradiated (800 cGy) and intravenously given
-C, On day 14 mice were humanely euthanized and A, spleens
FN- levels; C, CD4 and CD8 donor derived (H2b) chimerism.
-F, B6 (solid line), Sema4D/ T cells (dashed line), and BALB
epresentative of 1 of 3 similar experiments with a total of n  18/t T cells and less GVHD target organ damage. aema4D/ T Cells and GVL Effects
Preservation of in vivo donor T cell CTL is crit-
cal for maintenance of GVL after allo-BMT [22,34].
e therefore ﬁrst determined whether T cell CTL
as preserved in vivo post-allo-BMT. T cells were
arvested from the spleens of animals at 14 days post-
llo-geneic BMT. T cells from animals that received
llo B6 wt or CD100/ T cells (Figure 2B) dem-
nstrated similar cytolytic function towards P815 tar-
ets.
We further assessed whether the preservation of
TL functions held true despite the reduction in
roliferation in the absence of Sema4D on donor T
ells and would lead to maintenance of GVL. BALB/c
H2d) recipients where lethally irradiated with 800
Gy and injected with 400 syngeneic P815 (H2d) mas-
ocytoma cells along with allo-geneic wt BM and T
ells from either wt or Sema4D/ donors at the
ime of transplant (given on day 0 at the same time
f the BM inoculum). BALB/c animals that received
 106 BM cells and 0.5  106 BALB/c T cells along
ith P815 cells served as syngeneic controls. Prior to
he in vivo infusion, the P815 cells were transduced
ith a third-generation lentivirus as described in the
tudy Design section, which contained a GFP and
uciferase (Luc) construct to facilitate for in vivo
onitoring of the tumor burden in the same animals
nical GVHD scores. A-F, BALB/c (allogeneic) or B6 (syngeneic)
106 B6 wt BM and either 5.0  105 wt B6 or Sema4D/ T cells.
ient animals were analyzed for total H2b CD3 T cells; B, serum
vival, E, % weight loss, and F, GVHD scores compared to day 0.
tted line). #P 
 .01, *P 
 .05, **P 
 .02, ***P 
 .06. Results are
eic recipients of the control and SemaD4/ donors.and cli
5.0 
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i
a
w
d
n
w
j
o
c
o
(
d
w
(
n
b
c
t
t
i
S
l
v
i
D
m
W
d
n
m
o
m
[
m
S
p
g
T
S
w
c
l
O
I
F
t
S
f
p
e
S
n
C
F
(
B

p
w c recipi
R. Duran-Struuck et al.1300maging (BLI) (Figure 5A and B). Mice with leukemia
nd a BLI photon ﬂux of 1.0  1010/animal died
ithin 24 hours. This corresponded to a tumor bur-
en of 12 billion total cells/mouse. All of the synge-
eic recipients that did not receive tumor survived,
hereas all of the syngeneic recipients that were in-
ected with tumor died from the tumor without signs
f GVHD by day 12. By contrast, animals that re-
eived the allo-geneic T cells died by day 30 with signs
f GVHD (Figure 5C). The median survival time
MST) of tumor-bearing syngeneic animals was 10
ays, whereas MST for the allo-geneic recipients
as 25 days (B6 wt T cell recipients) and 24 days
Sema4D/ T cell recipients). However, allo-ge-
eic recipients showed evidence of tumor as detected
y BLI, but did so at a lesser intensity with a signiﬁ-
antly slower kinetics, thus demonstrating better an-
itumor responses than syngeneic controls. We fur-
her evaluated the magnitude of CTL responses by
ncreasing the tumor cell dose to 1000 cells.
ema4D/ T cell recipients demonstrated equiva-
ent median tumor free survival (MST day 21 wt
ersus day 22 Sema4D/) as the wt T cell recip-
ents in the higher tumor cell challenge (Figure 5D).
ISCUSSION
Our data demonstrate a novel role for Sema4D in
igure 4. Sema4D/ T cell recipients have improved immune re
allogeneic) or B6 (syngeneic) recipients were irradiated with 800 c
6 or Sema4D/ T cells. n  4 syn, n  6 allogeneic control, n 
60 post-BMT as described in Study Design of liver (A) small a
ost-BMT. E, Donor (H2b) CD3, CD4, and CD8 from recipi
t Tc (black bars) and allogeneic recipients of Sema4D/ B6 Todulating in vitro and in vivo allo-geneic responses. Se show that in the absence of Sema4D, T cells show
ecreased proliferation to allo-stimulation but not to
ominal antigens, decreased cytokine secretion, and
aintenance of CTL. Our data extend the previous
bservations demonstrating an important immuno-
odulatory role of Sema4D in autoimmune models
10,35]. In those studies, modulation of humoral im-
une responses were key to the observed effects of
ema4D [35]. By contrast, our experiments focused
rimarily on T cell-mediated allo-immune processes.
In our studies, Sema4D/ T cells in an allo-
eneic setting expanded less when compared with wt
cells. These results were further conﬁrmed by anti-
ema4D mAbs experiments. These MLR differences
ere associated with decreased production of the T
ell cytokines IL-2 and IFN-. These results are in
ine with previous observations that Sema4D/
VA TCR transgenic (Tg) animals produced less
FN- compared with wt OVA TCR Tg animals.
urthermore, crosslinking the T cell receptor with
he lectin concanavilin A [10], demonstrated that
ema4D/ T cell proliferation capacity was unaf-
ected (data not shown). In addition, consistent with
revious observations there were no signiﬁcant differ-
nces in CD4/CD8 ratios between the wt and the
ema4D/ animals [11]. Furthermore, there were
o differences in the absolute numbers of T cells or
D4/CD8 ratios in the puriﬁed T cells from the
ution and decreased GVHD target organ pathology. A-E, BALB/c
intravenously given 5.0  106 B6 wt BM and either 5.0  105 wt
a4D/ (A-C). Pathology scores of GVHD target organs on day
e intestine (B), and skin (C). D, Splenic cellularity on day  60
ens on day  60. Syngeneic recipients (white bars), allogeneic B6
ents (gray bars). One of 2 similar experiments. *P 
 .03.constit
Gy and
6 Sem
nd larg
ent spleema4D/ mice and the wt animals (CD4 64% 	
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CD100 and Allo-responses 1301% versus 68%	 4%, PNS) (Supplemental Figure
; available online at www.bbmt.org). All these ﬁnd-
ngs support the concept that the intrinsic prolifera-
ive responses of Sema4D/ are not altered, at least,
hen exposed to strong stimulatory signals.
These in vitro responses were further supported
y our in vivo studies demonstrating reduced
ema4D/ T cell numbers in the spleen of recipi-
nts 14 days post-BMT compared to recipients that
igure 5. Sema4D/ GVL effects. BALB/c (syngeneic H2d), B6
t (allogeneic H2b), or Sema4D/ (allogeneic H2b) recipients
ere irradiated with 800 cGy and intravenously given 5.0 106 BM
ells from BALB/c (syngeneic) or wt B6 (allogeneic groups) mice,
lus either 5.0  105 wt B6 (allogeneic control), Sema4D/ T
ells (experimental) or BALB/c T cells (syngeneic control). Four
undred P815 tumor cells were added into the BM inoculum of all
roups. A syngeneic [BALB/c¡BALB/c] control group did not
eceive a tumor. A, BLI images show progression of tumor growth
ystemically over 24 days n  4/group. Tumor burden in
ema4D/ T cell recipients is similar to B6 wt T cell recipients.
, Mean values 	 SEM for photon ﬂux/animal (n  4 mice). C-D,
umor-free survival n  6 syngeneic without tumor, n  10
yngeneic  P815, n  10 allo B6 wt T cell recipients  P815 and
 10 allo-Sema4D/ T cell recipients  400 P815 (C) or 1000
815 (D). Improved tumor-free survival in allogeneic T cell recip-
ents compared to the syngeneic recipients in both tumor chal-
enges. Sema4D/ allogeneic T cell recipients had a similar GVL
ffect as wt T cell control allogeneic recipients. *P 
 .01.eceived wt T cells. This demonstrates that Sema4D Deﬁciency does not completely abrogate the capacity
f the T cells to expand and secrete IFN- upon in
ivo allo-activation. Nonetheless, the reduction of
roliferation was still signiﬁcant enough to confer a
urvival beneﬁt from GVHD. However, when the T
ell dose was increased, consistent with lack of com-
lete abrogation of allo-proliferative responses, all of
he recipient animals succumbed to GVHD (data not
hown).
We also observed that Sema4D/ T cell had
omparable cytolytic effects with wt T cells. Although
ur CTL assays were normalized for CD8 T cells,
hese experiments included both CD4 and CD8 T
ells, and it is therefore conceivable that part of the
reservation in cytolytic responses was mediated
hrough CD4 help [22,36-38]. These studies nonthe-
ess support the notion that CD8 T cell CTL function
as not affected by CD100 deﬁciency, which possibly
ay have allowed for the GVL effects to remain
ntact. In the GVL studies most animals, however,
ventually succumbed to the leukemia despite small
umor doses. This is likely due to the small numbers of
cells that were utilized in our in vivo studies. We
aintained similar transplant conditions to evaluate
VL responses at the T cell dose that best produced
reduction in GVHD speciﬁc mortality. In any case,
oth Sema4D/ and wt T cells demonstrated a
lear GVL response as determined by the BLI and
umor-free survival when compared to syngeneic re-
ipients. In order to further support the fact that CD8
cell responses were not affected, we performed
minor mismatch CD8 T cell driven BMT
B6¡C3H.sw] [39]. In this primarily CD8 driven
ystem, the survival advantage of Sema4D deﬁciency
as not observed (data not shown). In summary, the
VL/CTL experiments together demonstrate that
ema4D/ CD8 T cells show no cytolytic deﬁ-
iencies when primed in vivo or in vitro.
It has been shown that Sema4D is required for the
aturation of DCs [10]. DC maturation may be an
mportant factor for explaining the differences in allo-
esponses observed by our Sema4D/ T cells.
D72, the receptor for Sema4D in the immune sys-
em, modulates APC activation by switching off CD72
nduced negative signals [5]. When we assessed DC
ytokine functional responses, we observed a signiﬁ-
ant reduction in TNF- and IL12p70 secretion after
n vitro cultures with allo-geneic Sema4D/ T cells
han allo-geneic wt T cells. The differences were
urther conﬁrmed by utilizing anti-Sema4D mAbs.
he differences in the DC function as determined by
he secretion of the pro-inﬂammatory cytokines were
lso maintained after treatment with LPS (data not
hown). We nonetheless did not observe signiﬁcant
ifferences in DC phenotype as determined by CD80/
D86 costimulatory molecule expression. However,
C phenotype does not always correlate with DC
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R. Duran-Struuck et al.1302mmune functions [40,41]. Alternatively, it is possible
hat Sema4D-CD72 interaction is sufﬁcient for alter-
ng cytokine secretion of DCs but not for costimula-
ory expression in the context of a strong allo-stimu-
us. Moreover, previous in vitro studies with CD40
ntibody induced DC stimulation showed that deﬁ-
iency of CD100 impaired the production of IL-12
nd prevented expression of CD80 [10]. Furthermore,
ddition of soluble Sema4D enhanced the activation
nd function of CD40 antibody treated DCs [10]. Our
bservations suggest that Sema4D expression on T
ells is necessary for the full activation and maturation
f allo-geneic DCs, which in return, further activates
he T cell responses.
Our data thus extend previous observations and
uggest a novel role for Sema4D in the activation and
aturation of APCs and in the modulation of in vivo
nd in vitro allo-responses. The modulation is signif-
cant enough to decrease GVHD and preserve CTL
nd GVL. Thus, targeting Sema4D might facilitate in
odulating allo-responses enough to reduce GVHD
ut preserve CTL-dependent GVL.
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